PM
UTHR icon

Parametrica Management’s United Therapeutics UTHR Stock Holding History

Parametrica Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,858
Closed -$335K – 123
2019
Q1 		$335K Buy
+2,858
New +$333K 0.71% 35
2018
Q1 		– Sell
-3,611
Closed -$534K – 420
2017
Q4 		$534K Buy
+3,611
New +$459K 0.34% 53

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Parametrica Management's UTHR Position: Q2 2019 in Review

Parametrica Management sold out of United Therapeutics (UTHR) in Q2 2019, closing a stake of 2,858 shares — an estimated $335K sold.

Parametrica Management first reported a position in UTHR in Q4 2017 and held it in 2 quarters. The position peaked at $534K in Q4 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q2 2019.

  • Parametrica Management reported no remaining United Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Parametrica Management sold 2,858 United Therapeutics shares in Q2 2019, an estimated $335K.
  • Parametrica Management first reported a position in United Therapeutics in Q4 2017 and held it in 2 quarters.
  • Parametrica Management's United Therapeutics position peaked at $534K in Q4 2017.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2019.

Based on Parametrica Management's 13F filing for Q2 2019, filed 13 Aug 2019.